Al-Saffar F, Ibrahim S, Patel P, Jacob R, Palacio C, Cury J
Mol Clin Oncol. 2016; 4(3):413-415.
PMID: 26998294
PMC: 4774480.
DOI: 10.3892/mco.2015.713.
Cleminson J, Austin N, McGuire W
Cochrane Database Syst Rev. 2015; (10):CD003850.
PMID: 26497056
PMC: 7156892.
DOI: 10.1002/14651858.CD003850.pub5.
Premachandra I, Scott K, Shen C, Wang F, Lane S, Liu H
ChemMedChem. 2015; 10(10):1672-86.
PMID: 26263912
PMC: 4682886.
DOI: 10.1002/cmdc.201500271.
Islam S, Singer M, Kulhanjian J
J Perinatol. 2014; 34(10):792-4.
PMID: 25263725
DOI: 10.1038/jp.2014.92.
George J, Sharma A, Dixit R, Chhabra N, Sharma S
J Pharmacol Pharmacother. 2012; 3(3):276-8.
PMID: 23129968
PMC: 3487281.
DOI: 10.4103/0976-500X.99445.
Antifungal therapy for newborn infants with invasive fungal infection.
Clerihew L, McGuire W
Cochrane Database Syst Rev. 2012; (6):CD003953.
PMID: 22696338
PMC: 7104293.
DOI: 10.1002/14651858.CD003953.pub3.
Fluconazole induced toxic epidermal necrolysis: a case report.
Ofoma U, Chapnick E
Cases J. 2010; 2:9071.
PMID: 20062708
PMC: 2803868.
DOI: 10.1186/1757-1626-2-9071.
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
Goa K, Barradell L
Drugs. 1995; 50(4):658-90.
PMID: 8536553
DOI: 10.2165/00003495-199550040-00007.
Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.
Peters B, Carlin E, Weston R, Loveless S, Sweeney J, Weber J
Drug Saf. 1994; 10(6):439-54.
PMID: 7917073
DOI: 10.2165/00002018-199410060-00003.
Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.
Perry C, Whittington R, McTavish D
Drugs. 1995; 49(6):984-1006.
PMID: 7641607
DOI: 10.2165/00003495-199549060-00009.
Adverse drug reactions to systemic antifungals. Prevention and management.
Perfect J, Lindsay M, Drew R
Drug Saf. 1992; 7(5):323-63.
PMID: 1418692
DOI: 10.2165/00002018-199207050-00003.
